Zacks Investment Research on MSN
TMO stock set to gain from the expansion of Gibco Bacto portfolio
Thermo Fisher Scientific TMO recently announced the expansion of its Gibco Bacto CD portfolio. The Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X) are two next-generation ...
Rising demand for gene and cell therapies, expanding mRNA vaccine pipelines, and increasing investments in GMP-compliant manufacturing facilities are driving growth in the viral vectors and plasmid ...
New formulations simplify microbial bioprocessing, helping innovators scale plasmid DNA and protein production with confidenceWALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world ...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco(TM) Bacto(TM) CD Supreme FPM Plus and Gibco(TM) Bacto(TM) CD Supreme Feed (2X), two ...
Genenta Science S.p.A. initiating with a Buy rating following a 90% stock surge after announcing a strategic partnership with ANEMOCYTE for LVV plasmid DNA technology. GNTA's lead cell therapy, ...
ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...
Experts at the Wellcome Sanger Institute, the University of Bath, the UK Health Security Agency (UKHSA) and their collaborators, analyzed over 40,000 plasmids from historical and present-day bacterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback